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Abstract
FK506 binding protein-like (FKBPL) and its peptide derivatives exert potent anti-angiogenic activity in vitro and in vivo and
control tumour growth in xenograft models, when administered exogenously. However, the role of endogenous FKBPL in
angiogenesis is not well characterised. Here we investigated the molecular effects of the endogenous protein and its
peptide derivative, AD-01, leading to their anti-migratory activity. Inhibition of secreted FKBPL using a blocking antibody or
siRNA-mediated knockdown of FKBPL accelerated the migration of human microvascular endothelial cells (HMEC-1).
Furthermore, MDA-MB-231 tumour cells stably overexpressing FKBPL inhibited tumour vascular development in vivo
suggesting that FKBPL secreted from tumour cells could inhibit angiogenesis. Whilst FKBPL and AD-01 target CD44, the
nature of this interaction is not known and here we have further interrogated this aspect. We have demonstrated that FKBPL
and AD-01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner; CD44 knockdown
abrogated AD-01 binding as well as its anti-migratory activity. Interestingly, FKBPL overexpression and knockdown or
treatment with AD-01, regulated CD44 expression, suggesting a co-regulatory pathway for these two proteins. Downstream
of CD44, alterations in the actin cytoskeleton, indicated by intense cortical actin staining and a lack of cell spreading and
communication were observed following treatment with AD-01, explaining the anti-migratory phenotype. Concomitantly,
AD-01 inhibited Rac-1 activity, up-regulated RhoA and the actin binding proteins, profilin and vinculin. Thus the anti-
angiogenic protein, FKBPL, and AD-01, offer a promising and alternative approach for targeting both CD44 positive tumours
and vasculature networks.
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Introduction
Angiogenesis is the formation of new blood vessels from pre-
existing vessels and its regulation is an essential component of
various developmental and wound healing pathways [1]; loss of
this regulation forms the basis of many pathological conditions [2].
Anti-angiogenic agents in clinical use target the VEGF pathway;
Macugen and Lucentis [3] for the treatment of macular
degeneration and Avastin [4], sunitinib [5] and sorafenib [6] for
targeting tumour growth. However, these VEGF-targeted anti-
cancer agents elicit modest response rates, generate resistance and
stimulate tumour metastasis in some instances [7]. Due to the
observed toxic effects [8] and limited efficacy, the FDA has
recently voted for the withdrawal of Avastin for metastatic breast
cancer treatment [9,10]. This highlights the demand for better
anti-angiogenic intervention strategies. We have recently reported
the development of novel peptides based on the anti-angiogenic
domain of the FKBPL protein. These have potent anti-angiogenic
activity but appear to target a CD44-dependent pathway,
differentiating them from the VEGF-targeting agents [11].
FKBPL belongs to the FK506 family of immunophilins [12,13],
with homology spanning the tetra trico peptide repeat (TPR)
domain which mediates its interaction with HSP90 [14]. FKBPL
plays a critical role in regulating steroid receptor complexes;
glucocorticoid [15], androgen [16] and estrogen receptors [17]. Its
regulation of estrogen signalling supported a role for FKBPL as a
prognostic and/or predictive biomarker of response to endocrine
therapy in breast cancer patients [18]. Our most recent data also
support an extracellular role for this protein in the regulation of
angiogenesis [11]. The active anti-angiogenic domain was
localised to a region distinct from the TPR domain and a
therapeutic peptide, AD-01, spanning this domain was developed.
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A preclinical candidate based on AD-01 has successfully complet-
ed toxicology studies with a view to initiating Phase I clinical trials
for solid tumours.
We have reported the anti-angiogenic activity of exogenously
administered FKBPL/AD-01 and their dependency on CD44
[11]. Here, we have further characterised the activity of the
endogenous protein as well as demonstrating an interaction
between FKBPL and AD-01 with CD44, their effect on the actin-
tubulin cytoskeleton and downstream signalling, leading to
deregulation of the RhoA-Rac pathway and consequential
inhibition of cell migration.
Materials and Methods
Cell Culture
HMEC-1 cells were obtained from the Centre of Disease
Control (Atlanta, USA); PC3 and MDA-MB-231 from the
American Type Culture Collection (Manassas, VA, USA). FKBPL
overexpressing MDA-MB-231 cells were derived from MDA-MB-
231 cells as described earlier [11]. All cell lines were authenticated
by short tandem repeat (STR) profiling carried out by the suppliers
and routinely tested for Mycoplasma. All cell lines were cultivated at
37uC in a humidified atmosphere of 5% CO2/95% O2 in
appropriate medium supplemented with 10% fetal calf serum
(FCS) (PAA, UK); HMEC-1 cells in MCDB-131, (Invitrogen,
UK), supplemented with epidermal growth factor (EGF, 10 ng/
ml) (Roche, UK) and L-glutamine (10 mM) (Invitrogen, UK);
MDA-MB-231 cells in DMEM (Invitrogen, UK) and MDA-MB-
231 FKBPL overexpressing cells were additionally supplemented
with G418 (Sigma, UK); PC3 cells in RPMI 1640 (Invitrogen,
UK).
Peptide Synthesis
AD-01 (NH2-QIRQQPRDPPTETLELEVSPDPAS-OH) and
scrambled AD-01 were synthesized and supplied by Almac Group
[11]. Purified AD-01 had .95% purity and an observed mass of
2704.0 kDa.
Cell Migration Assay
The in vitro migration assay is a modified version of the method
described by Ashton et al [19]. HMEC-1 or MDA-MB-231 cells
were plated in chamber slides (Lab-TekH, UK) and the confluent
monolayer was wounded using a sterile pipette tip and cells treated
with drug/antibody. The HMEC-1 monolayers were incubated
up to 12 h for the time course experiment and MDA-MB-231
monolayers for 18 h (,50% wound closure) after treatment. The
extent of ‘‘wound’’ closure was assessed blindly as previously
described [11]; 3 slides were processed in each treatment group
and the entire experiment repeated in triplicate. Data are
expressed as % wound size normalised to time zero (T0) control
or as % inhibition compared to a time matched control.
Subcellular Fractionation
Cytosol, membrane, cytoskeletal and nuclear fractions from
HMEC-1 and MDA-MB-231 monolayers were harvested using
the ProteoExtractH Subcellular Proteome Extraction Kit (Calbio-
chem, UK, Cat. no.539791). Specificity of the fractions was
determined using specific antibodies; Vimentin, Calpain and
Histone H1 diluted at 1:1000.
Western Blot Analysis
Log phase HMEC-1 or MDA-MB-231 cells were treated with
AD-01 at the stated dose and time or HA at 0.1 mg/ml (234 kDa,
Life core Biomedicals, USA) and cell lysates harvested using RIPA
(Radio-Immuno Precipitation Assay) buffer supplemented with
protease and phosphatase inhibitor cocktails (Roche, UK). Cell
lysates were reduced in Laemmli buffer (Sigma, UK) and subjected
to western blotting as reported earlier [11]. Blots were probed with
specific primary antibody and appropriate HRP-linked secondary
IgG (GE Healthcare, UK) at 1:10000, followed by detection with
Chemiluminescent Substrate (Millipore, UK).
Antibodies
CD44H (R&D Systems, cat: BBA10); FKBPL (Proteintech,
USA cat: 10060-1-AP); vinculin, profilin, cofilin, p-cofilin (Cell
signalling, cat: 4650, 3237, 3318 and 3313, respectively); RhoA
(BD Transduction, cat: 610848); anti-GAPDH and Actin (Sigma,
UK, cat: G9545 and A4700 respectively); Rac-1 (Millipore, MA
cat: 05–389). Histone H1 was obtained from Santa Cruz
Biotechnology. Polyclonal anti-AD-01 antibody was supplied by
Almac Discovery. All antibodies were used at 1:1000 unless
otherwise stated.
Rac Assay
This was carried out as described in our earlier paper [11].
Briefly, HMEC-1 monolayers were serum starved overnight, pre-
treated with AD-01 (1029 M) for 10 min/60 min, prior to
stimulation with fMLP (1 mM, Sigma, UK) for 30 sec at 37uC
and lysates subjected to Rac GTPase assay (Millipore, UK).
Flow Cytometry
MDA-MB-231 cells were harvested using the non-enzymatic
cell detachment buffer (Invitrogen, UK) and suspended at 26105
cells/100 ml, in phenol red free-DMEM with 1% BSA (bovine
serum albumin (Sigma,UK), flow buffer). Cells were incubated
with anti-CD44 antibody at 1–2 mg/ml for 1 h at 4uC on a
rotating wheel, washed three times with flow buffer and incubated
for a further 30 min at 4uC with Alexa 488-conjugated secondary
mouse antibody. The cells were further washed, re-suspended in
flow buffer and analysed on a BD LSR II Flow cytometer.
BIACORE Binding Assay
AD-01 (500 mM) was immobilised on an EDC/NHS activated
CM5 chip (GE Healthcare, USA), in the presence of 1 M NaCl
and 25 mM borate buffer (pH 8.5). This was followed by end-
capping with ethanolamine. The Rmax (,8000 RU) of anti-AD-
01 antibody (50 mg/ml) binding was assessed over a 10 min
injection period at 5 ml/min. In order to detect displacement of
the antibody/AD-01 interaction by CD44, a significantly lower
concentration of antibody was necessary (0.01 mg/ml). Binding of
the diluted antibody was inhibited in the presence of AD-01 (0–
1 mM) over a 4–8 min injection period at 10 ml/min. Competition
of this inhibition was used as a measure of real-time interaction
between AD-01 and CD44. Immunopurified CD44, or cytosol
and membrane extracts from MDA-MB-231 cells transfected with
CD44-targeted or non-targeted (NT) siRNA were used to assess
the interaction; recombinant human EGFR (R & D systems, cat:
344-ER) and a scrambled AD-01 peptide were used as negative
controls. Cell extracts were diluted 1:1 with HBS buffer, mixed
with the indicated concentrations of peptide in a 96-well plate
format and the complexes further mixed with anti-AD-01
antibody prior to automated injection. Binding analyses were
performed on BIACORE Q, using BIACORE Q Control and
Evaluation Software. Data transformation was carried out to
represent the binding efficiency across 5 independent experiments.
The relative binding of anti-AD-01 antibody in the presence of the
indicated concentrations of AD-01, was calculated as the
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percentage of the maximum resonance binding units at 0.001 mM
and 0.01 mM AD-01 in each experiment.
CD44 Immunopurification
CD44 (10 mg) or murine isotype control antibody was cross-
linked to agarose beads using CNBr (Pierce, UK) and incubated
overnight with cell extracts from MDA-MB-231 (1 mg/ml protein)
at 4uC. CD44 was eluted with elution buffer provided with the kit
and neutralised with 10 mM NaOH and used immediately for
binding assays; frozen immunoprecipitates were inactive.
Real-time PCR
RNA was extracted using STAT-60TM (AMS Biotechnology,
Europe) and reverse transcribed using the high capacity RNA-to-
cDNA kit (Applied Biosystems, Foster City, CA, cat 4387406).
RQ-PCR was performed using an ABI PRISM 7500 Sequence
Detector (Applied Biosystems, UK). Primer probe sets were
obtained from Roche Applied Science UK (FKBPL assay:
128226, CD44 assay: 110687 and GAPDH assay: 101128).
Reaction mixes (12.5 ml) contained 50 ng cDNA equivalents (or
control), 1x Taqman universal PCR master mix, 5 mM MgCl2,
0.2 mM each of dATP, dCTP and dGTP, 0.4 mM dUTP,
0.125 U AmpliTaq Gold, 2 mM primers (forward and reverse) and
200 nM TaqMan probe. Amplifications were performed with an
initial 20 sec incubation at 50uC, followed by treatment at 95uC
for 10 min. This was followed by 40 cycles of denaturing at 95uC
for 15 sec and annealing/extension at 60uC for 1 min. Data were
collected and analysed with Sequence Detector v1.6.3 software
(Applied Biosystems). Relative quantitative (Q-PCR) data was
calculated based on the ddCT method [20].
siRNA Transfections
MDA-MB-231 cells grown to 50% confluence were transfected
with either, 50 or 500 nM FKBPL targeted siRNA (Ambion, UK),
16 nM smart pool CD44 targeted siRNA or equivalent amounts of
NT siRNA using Dharmafect 1 (Dharmacon, Chicago, IL).
HMEC-1 cells were transfected at 80% confluence using
Lipofectin (Invitrogen, UK). Following a 72 h transfection the
cells were replated and subjected to either, migration assay,
binding assay, or western blotting 6 AD-01 (1029 M) treatment
using methods described above.
Immunoprecipitation
Cell lysates were prepared from HMEC-1 cells using BRIJ lysis
buffer (50 mM Tris-HCl, pH 8.0, 62.5 mM EDTA, 0.4% sodium
deoxycholate, 1% Brij 58, phosphatase inhibitor cocktail 1 and 2;
Sigma P2850 and P5726, respectively). Lysates (1 mg protein)
were incubated overnight at 4uC with 1 mg of primary antibody
(CD44 or FKBPL) or isotype controls; murine IgG2a (DAKO,
UK) and rabbit IgG (DAKO). Isotype control IgGs were used at
1:1000 concentration of primary antibody. Samples were
incubated with Protein A/G (20 ml, Invitrogen, UK) for 2 h at
4uC, washed with BRIJ lysis buffer, re-suspended in Laemmli
buffer and subjected to western blotting as described above.
Confocal Microscopy
MDA-MB-231 or HMEC-1 monolayers were grown to 50–
60% confluency in chamber slides (Lab-TekH, UK), wounded as
described above and treated with AD-01 (1029 M) for 24 h or
recombinant FKBPL (rFKBPL) (Fusion Antibody Ltd, UK)
(750 ng/ml) for 5 h. Cells were washed with PBS, fixed with 4%
paraformaldehyde, permeabilised with 0.1% Triton X-100 (Sig-
ma-Aldrich, UK) and blocked with 2% BSA. This was followed by
staining with either TRITC-phalloidin (Millipore, UK), anti-AD-
01 (1:1000) or anti-tubulin (1:500) antibody for 2 h at room
temperature, washed with PBS-T and stained for 2 h at room
temperature with a fluorescein isothiocyanate (FITC)/Alexa-488-
tagged secondary antibody. Finally, DAPI (1:1000) or propidium
iodide was added for 5 min, slides were mounted with Vectashield
mounting medium (Vector laboratories Inc., UK) and analysed on
Leica TCS SP5 Microscope (Germany) using 40x or 60x oil
immersion objective. Isotype controls included rabbit or mouse
IgG (1:10000).
Intravital Microscopy
Viewing chambers were inserted under the dorsal skin of female
Balb-c SCID mice. Fragments of MDA-MB-231 parental or
FKBPL overexpressing tumours were placed on the microvascular
bed and covered with a glass microslide. 21 days following tumour
implantation, mice were injected i.p. with FITC-dextran and
tumour vasculature was imaged using epi-florescence microscopy
at 100x and 20x magnification. Intravital images were analyzed by
ImageJ software (NIH, USA). Number of vessel branch points or
average vessel diameter (mm) were counted from 3D images; n = 5
mice per treatment group, 4 fields of view per tumour and 30
vessels per field. Animal experimentation was carried out under
the ethical approval of the Department of Health and Social
Service Protection, Northern Ireland taking into consideration the
3 Rs to ensure minimal suffering.
Statistics and Graphs
Statistical significance was determined either by T–test or one-
way or two-way ANOVA and line graphs were generated using
Prism Graphpad software.
Results
FKBPL is a Natural Anti-angiogenic Protein and is
Distributed within Several Intracellular Compartments
We have previously shown that FKBPL is secreted from
HMEC-1 and lung epithelial cells, L132, but not from the tumour
cell line, MDA-MB-231 [11]. To further characterize endogenous
FKBPL in terms of its cellular location and function, we carried
out western blot analysis on sub-cellular fractions of HMEC-1 and
MDA-MB-231 cells to gain insight into its localisation. Fraction-
ated cell extracts identified a wide cellular distribution profile for
FKBPL (Fig. 1A). It was present predominantly in the cytoplasm
and membrane of HMEC-1 and MDA-MB-231 cells at the
expected molecular weight (,42 kDa). Low levels were also
detected in the nuclear fraction of MDA-MB-231 cells. The
specificity of sub-cellular fractions was demonstrated by immuno-
blotting with specific compartmental markers which also acted as
loading controls for the samples used; vimentin for cytoskeletal
fractions, histone H1 for nuclear fractions and calpain for both
cytoplasmic and membrane fractions in this instance (Fig. 1A).
Furthermore, examination of FKBPL distribution by confocal
microscopy provided evidence of a punctate staining pattern
possibly indicating its presence in vesicular structures within the
cytoplasm (Fig. 1B) consistent with that observed for other
secretory proteins [21,22]. Acceleration of wound closure was
observed when HMEC-1 cells were treated exogenously with an
antibody (Fig. 1C) raised against the active domain of FKBPL
(anti-AD-01 antibody), suggesting that this antibody possibly binds
to secreted FKBPL to inhibit its anti-migratory activity. The role
of endogenous FKBPL in cell migration was further evaluated
using FKBPL targeted siRNA. In HMEC-1 cells, knockdown of
FKBPL expression accelerated 50% wound closure by 4 h in
FKBPL Regulates CD44 and the Cytoskeleton
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comparison to untransfected or NT siRNA transfected cells
(Fig. 1D). Conversely, in an in vivo experiment, xenografts of
MDA-MB-231 cells stably overexpressing FKBPL were imaged 21
days after implantation, following injection with FITC-dextran.
Intravital microscopy demonstrated impaired vascular develop-
ment in FKBPL overexpressing tumours compared to MDA-MB-
231 controls (Fig. 1E). FKBPL overexpressing xenografts had
increased vessel diameter and segment length whilst the number of
branch points was significantly reduced, indicative of reduced
vessel density which correlated with reduced tumour growth (data
not shown) in comparison to parental xenografts. These results
provide further evidence of the anti-angiogenic effects of tumour-
secreted FKBPL exerting its activity on murine vascular develop-
ment by outside-in signalling, probably via a cell surface receptor.
FKBPL and AD-01 Interact with CD44
We have demonstrated previously that rFKBPL and AD-01
mediate inhibition of cell migration in a CD44 dependent manner
[11]; however, the interaction with CD44 has not been
established. Here, we further investigated the possibility that
FKBPL or its peptide derivative, AD-01, could interact with
CD44. We used both CD44 and FKBPL antibodies to pull down
specific immune complexes in HMEC-1 cells (Fig. 2A). The CD44
antibody immunoprecipitated the ,55 kDa and the full length
80 kDa CD44 isoforms, consistent with observations from other
studies [23,24]. Interestingly, the FKBPL antibody clearly pulls
down the ,55 kDa and the full length ,80 kDa isoforms of
CD44, suggesting that endogenous CD44 and FKBPL interact
either directly or within a complex (Fig. 2A). Cdc42, a known
CD44 interacting protein, also pulled down these isoforms of
CD44; acting as a positive control. Murine and rabbit IgG were
used as negative controls to determine the specificity of the bands
Figure 1. FKBPL is present in various cell compartments and regulates cell migration and tumour vasculature. (A) Representative blot
demonstrating that FKBPL is present predominantly in the cytosol and membrane compartments of both HMEC-1 (H) and MDA-MB-231 (M) cells and
in the nuclear fraction of MDA-MB-231 cells. Protein extracts from each subcellular compartment probed with specific compartmental markers,
vimentin, calpain and histone-H1 were used as loading controls. (B) Representative confocal images (60x) of MDA-MB-231 and HMEC-1 cells fixed,
permeabilised and stained with DAPI (blue) and with anti-AD-01 primary antibody and Alexa-488 tagged secondary antibody demonstrating vesicular
staining for FKBPL (green); n = 3. (C) Anti-AD-01 antibody targets the active domain of FKBPL and accelerates HMEC-1 cell migration in comparison to
cells treated with an isotype control. Data points show means 6 SEM; n = 3 (D) FKBPL knockdown with siRNA accelerated migration of HMEC-1 cells
in comparison to un-transfected and NT-siRNA-transfected cells. Data points show means 6 SEM; n = 3. Cell migration was assessed using scratch
wound assay. Wound size is normalised to that of T0. p-value was determined using two-way ANOVA. (E) Intravital microscopy images (20x)
representing disruption of tumour vasculature in vivo in FKBPL-overexpressing MDA-MB-231 xenografts in comparison to those derived from
parental MDA-MB-231 cells. Tumours (21 days) were imaged using Epi-fluoresence microscopy following injection of mice with FITC-Dextran.
Quantification of vessel dynamics was carried out on 3D images using ImageJ software. n = 5 mice per treatment group (p-value was determined
using two-tailed T –test).
doi:10.1371/journal.pone.0055075.g001
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pulled by FKBPL and CD44 antibodies and non-specific bands
were detected at 39 kDa and 60 kDa in all samples. The other
bands shared between FKBPL and Cdc42 are likely to be non-
specific. The real-time interaction of AD-01 with CD44 was also
assessed in a cell free assay using surface plasmon resonance
(BIACORE assay). Unfortunately, commercially available recom-
binant CD44 was not suitable for this system, probably because
the recombinant protein was not fully glycosylated or folded
correctly when immobilised to CM5 surface and was therefore
unable to bind its natural ligand, hyaluronan (Fig. S1A). A
competitive assay system was therefore developed to assess the
interaction between AD-01 and CD44 extracted from fresh MDA-
MB-231 cell lysates (Fig. 2B). This binding assay was based on the
competitive ability of anti-AD-01 antibody to bind to AD-01 on
CM5 chip surface in the presence of increasing concentrations of
AD-01 in solution. An AD-01 interacting partner such as CD44
should compete with anti-AD-01 antibody binding to AD-01 in
solution, allowing the binding of anti-AD-01 antibody to the chip
surface which can be detected as an increase in response units
(Fig. 2B). AD-01 immobilised to the CM5 chip surface acted as a
high affinity ligand for the anti-AD-01 antibody and this binding
could be specifically competed by using AD-01 peptide (detectable
between 1–100 nM) in solution, in a dose dependent manner
(Fig. 2B). Competition was not observed using scrambled AD-01
peptide even at a high concentration (200 mM, Fig. 2B). Using this
BIACORE assay, CD44 immunopurified from MDA-MB-231
cellular fractions specifically bound AD-01 in solution resulting in
an increased response in comparison to lysates immunopurified
with a mIgG isotype or buffer control shown in a representative
sensogram chart (Fig. 2C). Due to the variability in absolute sensor
units between experiments arising from independently prepared
samples and chip surfaces, the data from 5 independent
experiments were normalised to the maximum in each group
and plotted as bar charts. The combined results showed a
significant interaction of immunopurified CD44 in comparison to
isotype control, in the presence of 1 nM AD-01 and this was
competed out at higher AD-01 concentrations as expected. The
inability of recombinant EGFR to affect the binding of anti-AD-01
antibody to the immobilised AD-01 acted as a negative control
(Fig. 2D). Thus AD-01 binds specifically to immunopurified CD44
in our binding assay.
CD44 Knockdown Abrogated AD-01 Binding as well as its
Anti-migratory Effect
To determine if AD-01 binding was truly CD44 dependent,
MDA-MB-231 extracts from cells transfected with CD44 targeted
siRNA, NT siRNA and control cells were subjected to the
BIACORE assay. Crude extracts from control or NT siRNA
demonstrated increased binding in comparison to the buffer
control. However, this binding was abrogated in cell extracts
derived from MDA-MB-231 cells transfected with CD44 targeted
siRNA (Fig. 3A). Furthermore, CD44 knockdown corresponded
phenotypically, resulting in abrogation of the AD-01 mediated
inhibition of cell migration in the same cell line, whilst AD-01 was
effective at inhibiting migration of control cells and cells
transfected with NT siRNA (Fig. 3B). The anti-migratory effect
of rFKBPL also showed a dependency on CD44 expression in
PC3 cells transfected with CD44 targeted siRNA (Fig. 3C),
indicating that FKBPL/AD-01 can mediate anti-migratory effects
in tumour cells by targeting CD44.
FKBPL and AD-01 Regulate Expression of CD44
To further investigate the molecular effects of AD-01 we
considered the potential for AD-01 to alter CD44 expression.
Treatment of MDA-MB-231 and HMEC-1 cells with AD-01
(1029 and 1027 M) resulted in an increase in CD44 protein levels;
similar increases in CD44 were seen in MDA-MB-231 cells stably
overexpressing FKBPL (Fig. 4A). Interestingly, AD-01 (1029 M)
also up-regulated FKBPL levels in MDA-MB-231 cells. These
effects were also observed at the transcriptional levels; in HMEC-1
cells, an up-regulation of CD44 at the mRNA level by qRT-PCR
was observed 8 h after treatment with AD-01 (Fig. 4B); the CD44
ligand, HA, also mediated an increase in CD44 mRNA levels but
the up-regulation at the protein level was marginal in comparison
to the effects mediated by AD-01. Furthermore, AD-01 and HA
also mediated a 1.5 fold increase in FKBPL mRNA levels in
HMEC-1 cells (Fig. 4C). Further, we investigated the effect of
endogenous FKBPL on CD44 expression. A dose dependent
knockdown of FKBPL was observed using 50 and 500 nM
FKBPL targeted siRNA. Concomitant with the level of FKBPL
knock-down there was a reduction in the expression of CD44
protein in the MDA-MB-231 and HMEC-1 cells (Fig. 4D). Finally,
FKBPL silencing also decreased cell surface CD44 levels in
comparison to control cells transfected with NT siRNA when
MDA-MB-231 cells were assessed by flow cytometry (Fig. 4E).
Thus endogenous FKBPL as well as AD-01 regulate the
expression of CD44.
AD-01 Disrupts the Actin Cytoskeleton and Creates an
Imbalance in the Rho-Rac Pathway
Although AD-01 up regulates CD44 expression, it appears to
mediate an anti-migratory phenotype on CD44 positive cells,
without effecting tumour or endothelial cell proliferation [11].
CD44 is involved in cell migration [25] and regulates the
cytoskeleton by interacting with the ERM (ezrin/radixin/moesin)
proteins. Therefore, to gain insight into the role of AD-01 and its
regulation of cytoskeletal components required for cell migration
we used confocal microscopy. Phalloidin staining of F-actin in
MDA-MB-231 cells treated with AD-01 was significantly altered
in comparison to the control cells (Fig. 5A). Untreated control cells
wounded and deemed activated for migration showed fine and
directional arrangement of F-actin enabling cell-cell contact. This
organised staining pattern was completely lost 24 h post-treatment
with AD-01, with cells showing intense cortical staining. HMEC-1
cells treated with rFKBPL showed a similar disruption in tubulin,
possibly contributing to loss of cell direction and migration
(Fig. 5B). This data is supported by evidence in several studies
which demonstrated that cooperation between microtubules and
the actin cytoskeleton is crucial in the control of cell shape,
contraction, and motility [26]. We followed this up with further
analysis of a number of proteins associated with Rho/Rac
signalling pathway. Activation of the Rho GTPase family of
proteins regulates the cytoskeletal structure of cells and their
migratory functions, therefore RhoA, vinculin and profilin were
chosen for further profiling in addition to Rac. An increase in
RhoA, profilin and vinculin levels was indeed observed at 24 h
following treatment and wounding of MDA-MB-231 cells with
AD-01 (Fig. 5C). This effect was seen in cells wounded and
deemed activated for directional migration; profilin and RhoA
were not up-regulated in response to AD-01 in non-wounded cells
which would not be activated for migration, indeed levels were
lower than the control.
Since the temporal and spatial regulation of Rho and Rac-1
GTPase activation is essential for co-ordinated cell migration, we
further examined the effect of AD-01 treatment on Rac-1 activity.
Pre-treatment with AD-01 for 10 and 60 min completely
abrogated the fMLP-mediated induction of Rac-1 activity, whilst
AD-01 did not affect levels of total Rac-1 protein (Fig. 5D). This
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supported our previous findings demonstrating an AD-01 medi-
ated inhibition of Rac-1 activation by serum as well as the CD44
ligand, HA [11]. Actin polymerisation is also regulated by the
phospho-cycling of cofilin and treatment with AD-01 for 3 h
inhibited the phosphorylation of cofilin therefore activating actin
polymerisation (Fig. 5E). HA, however up-regulated cofilin
phosphorylation maintaining its inactive state. Altogether the data
highlights the role of FKBPL and AD-01 on the CD44-cytoskeletal
pathway leading to inhibition of cell migration.
Discussion
FKBPL is a non-canonical member of the FK506 immuno-
philin family and has several distinct and important cellular roles
in regulating the process of malignancy [12–18]. Using overex-
pressed or rFKBPL, we have recently shown that FKBPL is an
anti-angiogenic protein and its activity resides in a 24 amino acid
region [11]. In this study, siRNA knockdown reversed the anti-
angiogenic effects of the endogenous protein. Although FKBPL
lacks the conventional signal peptide domain required for
secretion via Golgi-ER trafficking [27], we have previously
reported its secretion [11]. Further evidence of its extracellular
function comes from the observation that migrating endothelial
cells when exposed to anti-AD-01 antibody raised against
FKBPL’s active domain demonstrate accelerated migration,
possibly due to abrogation of the anti-migratory activity of
secreted FKBPL by the blocking antibody. Intracellular compart-
mentalisation of FKBPL in the cytosol, membrane and nuclear
fractions coupled with its punctate staining, indicative of vesicular
patterning, would support its various cellular roles in each of these
Figure 2. FKBPL and its peptide derivative, AD-01, bind CD44. (A) Representative western blot showing FKBPL co-immunoprecipitated with
CD44 in HMEC-1 cells; immuno-blotted with anti-CD44 antibody; n = 3; Cdc42 was used as a positive control for the CD44 interaction and rabbit and
murine IgGs were used as negative controls. (B) Schematic diagram of the Biacore assay using AD-01 immobilised on CM5 chip surface. Binding of
anti-AD-01 antibody to AD-01-CM5 surface was inhibited by AD-01 in solution in a dose dependent manner, with excellent sensitivity in lower
concentration range of peptide; 1–500 nM. Scrambled AD-01, used as a negative control, did not demonstrate any binding to anti-AD-01 up to
200 mM. Competition of the anti-AD-01 antibody interaction with its cellular partner/s results in increased binding of anti-AD-01 antibody on chip
surface. (C) Representative graph demonstrating that AD-01 specifically binds to CD44 immunoprecipitated from MDA-MB-231 cells using the assay
described. CD44 was immuno-purified from cell lysate and analysed using Biacore Q. Isotype control mIgG antibody was used as control. Bar charts
show the relative binding of anti-AD-01 antibody in presence of AD-01, calculated as the percentage of the maximum resonance binding units in the
presence of 0.001 and 0.01 mM AD-01. Data points show means 6 SEM of 5 independent experiments (p-value was determined by one way ANOVA).
(D) No competition of anti-AD-01 antibody binding to immobilised AD-01 was obtained in the presence of various concentrations of rEGFR indicating
a specificity of AD-01-CD44 interaction.
doi:10.1371/journal.pone.0055075.g002
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compartments in addition to its already well characterised
intracellular roles in nuclear steroid hormone receptor complexes
[15,17].
In vivo, FKBPL overexpressing tumour xenografts develop a
compromised tumour vasculature consistent with FKBPL’s role as
a secreted anti-angiogenic protein (Fig. 1E). Although secretion of
FKBPL has not been observed by the parental MDA-MB-231
cells, FKBPL overexpressing MDA-MB-231 cells demonstrated
FKBPL secretion in vitro [11]; this secretion, if occurring in vivo
would support the FKBPL-mediated anti-angiogenic effects on the
murine tumour endothelium. We have reported similar effects
with the exogenous FKBPL-based therapeutic peptide, AD-01, in
prostate xenografts in mice following systemic administration for
14 days [11]. This data further supports a role for FKBPL as a
secreted protein with anti-angiogenic activity, where high levels
also correlate with an increase in overall survival and metastasis-
free survival observed in clinical breast cancer data sets [17]. In
our previous study [11] we have reported that FKBPL’s anti-
migratory activity is restricted to cell lines expressing CD44. Here,
we provide further evidence to suggest that both endogenous
FKBPL and its peptide derivative, AD-01, interact with CD44
resulting in cytoskeletal disruption. In order to further interrogate
this interaction, surface plasmon resonance was employed.
However, attempts to establish an assay system between AD-01,
rFKBPL, and CD44’s natural ligand, HA, using rCD44 immo-
bilised on a Sensor Chip CM5 in a cell free system were
unsuccessful (Fig. S1). Since the FKBP family of proteins are
involved in protein-protein interactions [28], the possibility that
the FKBPL/AD-01 and CD44 interaction requires other factors/
proteins cannot be ruled out. To address this, an indirect assay was
constructed to identify AD-01 interactions with CD44 derived
directly from fresh cell extracts. In MDA-MB-231 cells, binding of
immunopurified CD44 with AD-01 was detected and this
interaction was more significant at lower concentrations of AD-
01 as the interaction with anti-AD-01 antibody was competed out
at the higher AD-01 concentrations. Knockdown studies using
Figure 3. Binding and anti-migratory activity of AD-01 is dependent on CD44. (A) Representative graph demonstrating extracts of MDA-
MB-231 un-transfected control/NT siRNA transfected cells render increased binding of anti-AD-01 antibody to AD-01 immobilised on CM5 chip
surface using the specific binding assay described in Fig. 2. This binding was abrogated in lysates derived from CD44 knockdown cells. Buffer control
comprised of HBS buffer with indicated amounts of AD-01. Bar charts demonstrate significant abrogation of this binding in the presence of 1029 M
AD-01 in lysates from cells transfected with CD44 siRNA. Data points show means 6 SEM; n = 4. (B) Treatment with AD-01 at 1029 M results in
inhibition of migration in un-transfected and NT siRNA transfected MDA-MB-231 cells. This inhibition of migration was abrogated upon CD44
knockdown using targeted siRNA. Data points show means 6 SEM; n = 5. (p-value was determined using one-way ANOVA). (C) Anti-migratory effect
of rFKBPL 1500 ng/ml was abrogated in PC3 cells transfected with CD44 targeted siRNA in comparison to those transfected with scrambled siRNA;
n = 3.
doi:10.1371/journal.pone.0055075.g003
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crude cell extracts of MDA-MB-231 provided further evidence
that AD-01 has a requirement for CD44 to mediate its anti-
migratory activity.
We then focused on the activation/inactivation of candidate
proteins that are known to be involved in the Rho/Rac/CD44
pathway. CD44 has a well-established role in breast cancer
invasion/metastasis [29] and angiogenesis [30] and is subject to
extensive splicing and post-translational modification [31]. There
are a number of reports correlating the expression of CD44
variants in metastatic spread [32,33], and their therapeutic
targeting for tumour control [34,35]. The standard isoform,
CD44s, has also been attributed with tumour suppressor functions
in carcinomas of the breast [36–38], prostate [39,40] and colon
[41]. The pro- and anti-tumour functions of CD44 are not merely
determined by its presence but are also governed by other factors;
ligand binding, isoforms, structure, post-translational modifica-
tions, complexing of its cytoplasmic tail with other proteins,
subcellular locations and downstream signalling pathways [42,43].
Upon binding to cell surface CD44, AD-01 as well as endogenous
FKBPL, trigger downstream signalling events and up-regulate
CD44 expression at the protein and mRNA level. The AD-01-
mediated up-regulation of FKBPL would also possibly result in the
modulation of CD44 levels, as we demonstrate that siRNA-
mediated knockdown or stable overexpression of FKBPL correlate
with CD44 levels (Fig. 4); it is highly likely that these two
interacting proteins therefore regulate each other’s activity and
mediate downstream effects on cell migration, leading to an
upregulation of signalling through the focal adhesion pathway and
an increase in RhoA and its effector proteins (Fig. 5). Expression of
actin-binding proteins, profilin and vinculin, is associated with
decreased invasion, and cell migration [44,45], supporting our
own data where we demonstrate an AD-01-mediated increase in
profilin and vinculin correlating with decrease cell motility. A
balance of RhoA and Rac1/Cdc42 GTPase activity is required
during cell migration. Whilst Rac1/Cdc42 activity mediates
leading edge migration, RhoA acts at the trailing edge and there
is an inverse relation between the two GTPases [46,47]. AD-01
treatment appears to disrupt the cytoskeleton and affects the
balance of Rho-Rac activity leading to a loss of cell rolling
dynamics and cell-cell communication eventually inhibiting cell
migration. In support of our data, constitutive activation of RhoA,
mediated similar effects on stress fibre formation and cytoskeletal
Figure 4. AD-01 and FKBPL regulate CD44 expression. (A) Treatment with AD-01 up-regulated CD44 expression. Representative blots of cell
lysates from MDA-MB-231/HMEC-1 treated with AD-01 or HA (0.1 mg/ml) for 24 h and MDA-MB-231/FKBPL overexpressing cells, probed with anti-
CD44, FKBPL or GAPDH antibodies (n = 3). Transcriptional regulation of CD44 (B) and FKBPL (C) upon treatment with AD-01/HA was assessed using
quantitative RT-PCR. Data points show mean fold change 6 SEM in FKBPL or CD44 expression in cDNA prepared from cells treated with AD-01 in
comparison to control untreated cells; n = 3. (D) Representative western blots demonstrating dose dependent down-regulation of FKBPL upon
transfection with FKBPL targeted siRNA for 72 h, resulting in a corresponding down-regulation of CD44 protein; n = 3. (E) Flow cytometric analysis of
cell surface expression of CD44 in MDA-MB-231 cells transfected with FKBPL siRNA in comparison to NT siRNA and stained with anti-CD44 and Alexa-
488 conjugated secondary antibody; n = 3.
doi:10.1371/journal.pone.0055075.g004
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disruption leading to impaired motility in MDA-MB-231 cells
[48]. Whilst there appeared to be a downregulation of RhoA and
profilin following addition of AD-01 in non-wounded cells
(Fig. 5C), this would be irrelevant to a developing vasculature
where endothelial cells would be activated to migrate, although
further investigation would be required to address this effect.
Additional evidence towards the disruption of actin comes from
the AD-01 mediated effect on the activation of cofilin which is also
reported to result in inhibition of collective cell migration [49] due
to inhibition of Rac-1 activation. Whilst it is clear that FKBPL and
AD-01 bind and regulate CD44, the precise mechanisms leading
to their downstream effects on the cytoskeleton are not clear, nor
whether the changes we see in cell signalling are the cause or
consequence of cytoskeletal disruption. It is likely that FKBPL and
its peptide derivatives bind to a CD44 complex at the cell surface
are internalised via CD44 and mediate direct effects on the
cytoskeleton leading to the loss of functional cell migration and
consequent inhibition of Rac-1 activity. Interaction of FKBPL
with the cytoskeleton via complexing with microtubule binding
protein dynamitin has been reported earlier [15]. Inhibition of
Rac-1 possibly leads to up-regulation of RhoA and downstream
effector molecules resulting in increased focal adhesion and
cortical staining. Since normal migratory functions of the cell
are compromised, signalling for further CD44 synthesis could be
initiated, consistent with the up-regulation demonstrated upon
AD-01 treatment. Further investigation into the effect of AD-01 on
CD44 internalisation and its interactions with ERM, ankyrin and
RHAMM, will provide a better understanding of this mechanism
and further insight into the role of CD44 in modulating the
cytoskeleton and tumourigenesis.
Conclusions
We have identified that FKBPL and its peptide derivative, AD-
01, can interact with CD44, regulate CD44 signalling and
expression levels and interfere with Rho/Rac signalling in
wound-activated cells leading to reduced cell migration. Given
Figure 5. AD-01 and FKBPL mediate cytoskeletal changes and AD-01 disrupts the RhoA-Rac1 dynamics. (A) Confocal images (60x)
representing the changes in phalloidin/F-actin dynamics in MDA-MB-231 upon wounding and treatment with AD-01 (1029 M) for 24 h; n = 3. Treated
monolayers were fixed and stained with TRITC-phallodin (red) and DAPI (blue). Intense actin staining was accompanied by the loss in cell direction
and communication. (B) Images (40x) representing disruption in tubulin distribution in HMEC-1 cell monolayers, wounded and treated with rFKBPL
750 ng/ml for 5 h. Fixed monolayers were stained for tubulin, followed by FITC conjugated secondary antibody (green) and nucleus with PI (red). (C)
RhoA expression was increased after wounding and treatment with AD-01 for 24 h, resulting in a concomitant increase in the downstream actin
binding proteins vinculin and profilin. Cells monolayers were treated with AD-01 (6 wounding) for 24 h and total cell lysates were subjected to
immuno blotting as indicated. (D) Treatment with AD-01 (1029 M) for 10/60 min inhibited fMLP induction (30 sec) of GTP-Rac-1 in HMEC-1 cells. Cell
lysates of treated monolayers were subjected to Rac GTPase pull down assay; n = 3. (E) Representative western blots and quantitative densitometric
analysis demonstrating an inhibition of cofilin phosphorylation after treatment with AD-01. HA treatment up-regulated cofilin phosphorylation
maintaining its inactive state. HMEC-1 cell monolayers were treated with AD-01 for 3 h or HA for 10 min, and the extracted membrane fractions were
subjected to immunoblotting with cofilin/p-cofilin; n = 3.
doi:10.1371/journal.pone.0055075.g005
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limited success from VEGF-targeting approaches and positive
correlations between CD44 expression and enhanced angiogenic
properties of cancer cells [50], the FKBPL peptide may prove
advantageous in the field of novel anti-angiogenic agents currently
in clinical use.
Supporting Information
Figure S1 Sensograms demonstrating lack of binding of (A)
CD44 ligand, HA (0.1 mg/ml); anti-CD44 antibody was used as a
positive control or (B) AD-01, Scr AD-01, rFKBPL to rCD44
immobilised on CM5 chip. The data indicate that the process of
immobilisation mediated a conformational change in the active
site of CD44, preventing binding, even to its natural ligand HA,
although immunogenicity is retained as demonstrated
(TIFF)
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